Clinical Trials Browser

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT06322342 2025-12-26

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Neuroinflammatory Diseases, Brain Neoplasms, Glioma, Meningioma, Multiple Sclerosis, Neoplasms, Neurilemmoma, Neurofibroma, Neuroma, Acoustic, Central Nervous System Neoplasms

NCT02728388 2025-05-08

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Phase 2 Recruiting

30 enrolled

CNS

Neurofibroma, Neurofibromatosis 1

NCT03231306 2025-05-02

NF108-BINI

Phase 2 Completed

45 enrolled 8 charts

CNS

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

NCT02332902 2023-12-20

DCLNF1

Phase 2 Completed

24 enrolled 4 charts

CNS

Neurofibroma, Neurofibromatosis 1

NCT00846430 2023-08-30

Medical Treatment of "High-Risk" Neurofibromas

Phase 2 Completed

9 enrolled 9 charts

CNS

Neurofibroma, Neurofibromatosis 1

NCT02096471 2019-01-10

MEK Inhibitor

Phase 2 Completed

19 enrolled 14 charts

CNS

Neurofibroma, Neurofibromatosis 1

NCT00021541 2018-04-17

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Phase 2 Completed

62 enrolled 13 charts

CNS

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT02988726 2017-07-26

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma

Phase 2 Terminated

3 enrolled

CNS

Neurilemmoma, Neurofibroma, Central Nervous System Neoplasms

Clinical Trials

ReNeu

Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

NF108-BINI

DCLNF1

Medical Treatment of "High-Risk" Neurofibromas

MEK Inhibitor

R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas

Antineoplaston Therapy in Treating Patients With Neurofibroma and Schwannoma